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1. INTRODUCTION {#mgg3996-sec-0005}
===============

Autism spectrum disorder (ASD), which belongs to a group of neurobehavioral syndromes, is characterized by significantly impaired social interaction and communication as well as by restricted, repetitive, and stereotyped patterns of behaviors, interests, and activities (Johnson, Myers, & American Academy of Pediatrics Council on Children With, [2007](#mgg3996-bib-0017){ref-type="ref"}). The prevalence of ASD is estimated to be 1:59 children and 1:100 adults (Baio et al., [2018](#mgg3996-bib-0003){ref-type="ref"}; Brugha et al., [2011](#mgg3996-bib-0006){ref-type="ref"}). The rate of ASD is higher in males than in females (4:1), which is higher than those of Down syndrome and epilepsy. Developmental delays are observed in approximately 40% of individuals with ASD, and approximately 70% show some level of intellectual disability. ASD has strong genetic contributions, and single‐gene disorders are recognized as causative in less than 20% of ASD cases (Herman et al., [2007](#mgg3996-bib-0014){ref-type="ref"}). The most consistently reported single gene disorders associated with ASD are fragile X syndrome, Rett syndrome, and tuberous sclerosis. The prevalence of fragile X syndrome among subjects with ASD is 1.5%--3% (Clifford et al., [2007](#mgg3996-bib-0010){ref-type="ref"}). The genetic etiology of ASD is complex.

Chromosomal microarray analysis (CMA) examines gross chromosomal structural abnormalities and can detect deletions and duplications as well as the size and presence of known genes within a chromosomal region. The most common microarray abnormalities in ASD involve the chromosome regions 15q11‐q13, 16p11.2, and 22q11.2 (Carter & Scherer, [2013](#mgg3996-bib-0008){ref-type="ref"}; Roberts, Hovanes, Dasouki, Manzardo, & Butler, [2014](#mgg3996-bib-0031){ref-type="ref"}). In the clinical setting, CMA, which has a diagnostic yield ranging from 7.0% to 9.0%, is recommended as the first tier test for children and adults presenting with ASD (Battaglia et al., [2013](#mgg3996-bib-0005){ref-type="ref"}; McGrew, Peters, Crittendon, & Veenstra‐Vanderweele, [2012](#mgg3996-bib-0025){ref-type="ref"}; Shen et al., [2010](#mgg3996-bib-0034){ref-type="ref"}).

Technological improvements have led to tremendous advances in our understanding of the genetic basis of ASD over the past 10 years. Most genomic studies on ASD using next‐generation sequencing (NGS) have focused on protein‐coding regions and analyzed trio information to identify sequence‐level de novo mutations (De Rubeis et al., [2014](#mgg3996-bib-0011){ref-type="ref"}; Iossifov et al., [2014](#mgg3996-bib-0015){ref-type="ref"}, [2012](#mgg3996-bib-0016){ref-type="ref"}; Neale et al., [2012](#mgg3996-bib-0028){ref-type="ref"}; O\'Roak et al., [2012](#mgg3996-bib-0029){ref-type="ref"}; Sanders et al., [2012](#mgg3996-bib-0033){ref-type="ref"}). Hundreds of genes have been implicated in the cause of ASD. The identification of new genes involved in ASD has made this condition a strong candidate for genome‐based diagnostic testing, which consists of CMA and NGS, as well as whole‐genome sequencing (WGS) and whole‐exome sequencing (WES).

Recently, Guo et al. applied WGS, WES, and CMA to investigate genomic variants in ASD families and compared the performances of WGS and WES for use in diagnostic testing (Guo et al., [2019](#mgg3996-bib-0012){ref-type="ref"}). The authors reported the diagnostic utility of WGS for detecting disorder‐related variants (particularly multiple rare‐risk variants that contribute to phenotypic severity in individuals with ASD), identifying genetic heterogeneity in multiplex ASD families and predicting novel ASD‐associated genes for future study.

In this study, we aimed to define causative or susceptibility variants for ASD and their copy number variants by CMA. We studied five subjects who are typical of those seen in developmental pediatric clinics. The sample was stratified based on the clinical phenotype of the patients.

2. MATERIALS AND METHODS {#mgg3996-sec-0006}
========================

2.1. Subjects with ASD {#mgg3996-sec-0007}
----------------------

Five patients with a clinical diagnosis of ASD were enrolled in the study. Autism screening was performed using the Autism Behavior Checklist, Taiwanese version (ABC‐T), which was modified from the third edition of the Autism Behavior Checklist of Autism Screening Instrument for Education Planning (Krug, Arick, & Almond, [1980](#mgg3996-bib-0020){ref-type="ref"}). Family members were also enrolled for inheritance pattern analysis. Blood samples were obtained, and genomic DNA was extracted using the Nucleospin® Blood Kit (Macherey‐Nagel, GmbH & Co. KG, Duren, Germany). This study was approved by the China Medical University Hospital (CMUH105‐REC1‐039).

2.2. Single‐nucleotide polymorphism (SNP) array analysis {#mgg3996-sec-0008}
--------------------------------------------------------

DNA samples (250 ng) were hybridized to the Affymetrix CytoScan 750K array according to the manufacturer\'s instructions. The 750K array contained greater than 750,000 markers for copy number analysis and 200,000 SNP probes for genotyping. The following standard experimental procedures were performed: digestion, ligation, polymerase chain reaction (PCR), PCR purification, fragmentation, labeling, hybridization, washing, staining, and scanning. After hybridization, GeneChip Scanner 3000 7G, Affymetrix GeneChip Command Console software, and Affymetrix ChAS 2.0 software were used for scanning the arrays, extracting the images, and performing the analysis, respectively. All data had to pass quality control (QC) metrics including the median of the absolute values of all pairwise differences ≤ 0.30, SNPQC ≥ 15, and a waviness standard deviation ≤ 0.12.

2.3. WES {#mgg3996-sec-0009}
--------

In total, 100 ng of genomic DNA based on Qubit quantification was mechanically fragmented on a M220 focused ultrasonicator Covaris (Covaris, Woburn, MA, USA), and QC was performed using an Agilent Bioanalyzer 4200 (Agilent Technologies, Santa Clara, CA, USA) to ensure an average fragment size of 150--200 bp. End repair, A‐tailing, adaptor ligation, and enrichment of DNA fragments were then performed. A 200--400 bp band was gel‐selected, and exome capture was performed using a TruSeq Exome Library Preparation Kit (Illumina, San Diego, CA, USA). The DNA library was quantified in the Qubit 3.0 Fluorometer (Invitrogen) and Agilent 4200 Bioanalyzer (Agilent Technologies). Samples were sequenced on an Illumina NextSeq500 platform and 150‐bp paired‐end reads were generated.

2.4. Data analysis {#mgg3996-sec-0010}
------------------

Base calling and quality scoring were performed by an updated implementation of real‐time analysis on the NextSeq500 system. Bcl2fastq Conversion Software was used to demultiplex data and convert the BCL files to FASTQ files. Sequenced reads were trimmed for low‐quality sequences and mapped to the human reference genome (hg19) using the Burrows--Wheeler alignment (Li & Durbin, [2009](#mgg3996-bib-0023){ref-type="ref"}). Finally, SNPs and small insertions/deletions were detected using Genome Analysis Toolkit and VarScan using their default settings (Koboldt et al., [2012](#mgg3996-bib-0019){ref-type="ref"}; McKenna et al., [2010](#mgg3996-bib-0026){ref-type="ref"}). ANNOVAR was used to annotate the VCF files by gene, region, and filters from several other databases (Wang, Li, & Hakonarson, [2010](#mgg3996-bib-0038){ref-type="ref"}). Finally, we annotated the mutations using several databases and tools, including dbSNP (build 147), GnomAD (<http://gnomad-old.broadinstitute.org/>), Denovo‐db (<http://denovo-db.gs.washington.edu/denovo-db/>), ClinVar, Polyphen‐2, SIFT, and CADD (Adzhubei et al., [2010](#mgg3996-bib-0001){ref-type="ref"}; Kircher et al., [2014](#mgg3996-bib-0018){ref-type="ref"}; Kumar, Henikoff, & Ng, [2009](#mgg3996-bib-0021){ref-type="ref"}; Landrum et al., [2014](#mgg3996-bib-0022){ref-type="ref"}; Sherry et al., [2001](#mgg3996-bib-0035){ref-type="ref"}; Turner et al., [2017](#mgg3996-bib-0037){ref-type="ref"}). Pathways were analyzed using STRING (<https://string-db.org>). Additionally, ASD‐related genes reported in the public databases OMIM and AutDB were selected (Basu, Kollu, & Banerjee‐Basu, [2009](#mgg3996-bib-0004){ref-type="ref"}).

2.5. Variant validations and segregation analysis {#mgg3996-sec-0011}
-------------------------------------------------

We used PCR and Sanger sequencing to validate candidate variants from WES. Segregation analysis was carried out on family members. PCR primers were designed using Primer3 (<http://bioinfo.ut.ee/primer3-0.4.0/>). Table [S1](#mgg3996-sup-0001){ref-type="supplementary-material"} lists the designed primers. The products were directly sequenced with an ABI PRISM BigDye kit using an ABI 3130 DNA sequencer (Applied Biosystems). Sequencing results were analyzed using the software Chromas, version 2.23.

3. RESULTS {#mgg3996-sec-0012}
==========

Following QC of the WES data, five probands were analyzed further and confirmed by Sanger sequencing. For these, a mean coverage depth of 141X was achieved (Table [1](#mgg3996-tbl-0001){ref-type="table"}). Patient 1, a 21‐year‐old male who presented with autism combined with epilepsy, had an ABC‐T score of 28 (Table [3](#mgg3996-tbl-0003){ref-type="table"}). The 750K microarray showed a 2q13 duplication (482.154 kbp) containing three OMIM genes (*RGPD6*, *MALL*, and *NPHP1*). WES revealed four rare variants in *SHANK3* (c.3658A \> G; p.T1220A; rs751183635), *DNAH10* (c.2800C \> T; p.R934C; rs757691040), *ESR2* (c.1228C \> T; p.R410C; rs528840784), and *NAALADL2* (c.1424G \> A; p.R475H; rs372908344) (Table [2](#mgg3996-tbl-0002){ref-type="table"}). Among them, SHANK3 and ESR2 are involved in negative regulation of signal transduction (GO:0,009,968). Furthermore, three pathogenic mutations were observed, *SMPD1* (p.P186L), *FUT2* (p.R202X), and *BCHE* (p.T343fs).

###### 

Whole‐exome sequencing alignment and mean base depth statistics for 5 probands for the analysis

  Case      Total raw reads   Total effective reads   Reads mapped to genome   Average read depth of target regions   Number of SNVs on target
  --------- ----------------- ----------------------- ------------------------ -------------------------------------- --------------------------
  ASD23     172,869,310       159,621,404             159,588,187              139.246                                34,233
  ASD24     186,622,966       172,125,108             172,094,954              143.877                                34,284
  ASD25     192,186,388       173,661,734             173,616,740              126.054                                34,093
  ASD26     191,244,742       176,442,474             176,407,661              154.055                                34,942
  ASD27     167,228,010       153,870,614             153,839,987              141.935                                33,945
  Average   182,030,283       167,144,267             167,109,506              141.033                                34,299
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###### 

Summary of the rare variants in autism‐related genes detected in this study

  Proband ID (Gender)   Mode of Inheritance   Identified Variant                                   Genotype                                           Functional prediction   MAF   Abnormal chromosomal microarray data                                                                                                                                    
  --------------------- --------------------- ---------------------------------------------------- -------------------------------------------------- ----------------------- ----- -------------------------------------- ------------------- ------------------- ------------- --------- -------- -------------- ------------- -------------------------- ----
  ASD23 (M)             AD                    *SHANK3*                                             c.3658A \> G                                       p.T1220A                A/G   A/G                                    A/A                 NA                  NA            NA        0        Dup            2q13          110,498,141--110,980,251   3
  AD                    *DNAH10*              c.2800C \> T                                         p.R934C                                            C/T                     C/T   C/C                                    Probably damaging   Deleterious         34            0.0001                                                                     
  AD                    *ESR2*                c.1228C \> T                                         p.R410C                                            C/T                     C/C   C/T                                    Probably damaging   Deleterious         23.3          0.0006                                                                     
  AD                    *NAALADL2*            c.1424G \> A                                         p.R475H                                            G/A                     G/A   G/G                                    Possibly damaging   Deleterious         23.1          0.0008                                                                     
  ASD24 (M)             AD                    *DLGAP3*                                             c.1759G \> C                                       p.G587R                 G/C   G/C                                    G/G                 Possibly damaging   Deleterious   27        0.0004   Not detected                                            
  AD                    *SLC1A2*              c.1091G \> A                                         p.R364H                                            G/A                     G/A   G/G                                    Probably damaging   Deleterious         35            0.0001                                                                     
  AD                    *CLTCL1*              c.1061G \> A                                         p.R354H                                            G/A                     G/A   G/G                                    Probably damaging   Deleterious         24.9          0.0009                                                                     
  ASD25 (M)             AD                    *WFS1*                                               c.2144G \> T                                       p.S715I                 G/T   G/G                                    G/T                 Possibly damaging   Deleterious   25        0.0002   Dup            1q21.1q21.2   145,895,746--147,844,777   10
  AD                    *TNN*                 c.1681T \> C                                         p.Y561H                                            T/C                     T/T   T/C                                    Probably damaging   Deleterious         25.7          0.0001                                                                     
  AD                    *JMJD1C*              [a](#mgg3996-note-0002){ref-type="fn"}c.6344A \> C   p.F2115C                                           A/C                     A/C   A/A                                    Probably damaging   Deleterious         29.9                                                                                     
  AD                    *APP*                 c.1748A \> G                                         p.E583G                                            A/G                     A/A   A/G                                    Possibly damaging   Deleterious         28.8          0.0001                                                                     
  AD                    *SYNE1*               c.9878C \> T                                         p.S3293F                                           C/T                     C/T   C/C                                    Probably damaging   Deleterious         32            0.0005                                                                     
  AD                    *MPP6*                c.61G \> A                                           p.D21N                                             G/A                     G/G   G/A                                    Probably damaging   Deleterious         33            0.0003                                                                     
  AD                    *MCC*                 c.60_61insAGC                                        p.G21delinsSG                                      Het                     WT    Het                                    NA                  NA                  NA            0                                                                          
  ASD26 (M)             AD                    *TSC2*                                               c.5418T \> G                                       p.F1806L                T/G   T/G                                    T/T                 Probably damaging   Deleterious   23.2      0.0001   Not detected                                            
  AD                    *SETBP1*              c.2842C \> T                                         p.R948C                                            C/T                     C/T   C/C                                    Probably damaging   Deleterious         24.5          0.0002                                                                     
  AD                    *TCF12*               [a](#mgg3996-note-0002){ref-type="fn"}c.770C \> T    p.R257H                                            C/T                     C/C   C/T                                    Probably damaging   Deleterious         28.1                                                                                     
  AD                    *LZTS2*               c.1259G \> A                                         p.R420Q                                            G/A                     G/A   G/G                                    Probably damaging   Deleterious         28.6          0.0003                                                                     
  AD                    *BIRC6*               [a](#mgg3996-note-0002){ref-type="fn"}c.6600G \> T   p.Q2200H                                           G/T                     G/T   G/G                                    Probably damaging   Deleterious         26.7                                                                                     
  AD                    *EPHA6*               c.527A \> C                                          p.N176T                                            A/C                     A/C   A/A                                    Probably damaging   Deleterious         24.9          0.00003                                                                    
  X‐Y pseudoautosomal   *ASMT*                c.451G \> A                                          p.G151S                                            G/A                     G/A   G/G                                    NA                  NA                  NA            0.0005                                                                     
  ASD27 (M)             De novo               *NHS*                                                [a](#mgg3996-note-0002){ref-type="fn"}c.20T \> C   p.I7T                   C/C   T/T                                    T/C                 Probably damaging   Deleterious   23.9               Dup            9q33.1        118,921,750--120,012,115   3

Abbreviations: UF, unaffected father; UM, unaffected mother.

Variants were not reported.
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Patient 2, an 8‐year‐old male, had an ABC‐T score of 27 (Table [3](#mgg3996-tbl-0003){ref-type="table"}). The 750K microarray revealed no abnormalities. WES revealed three rare variants in *DLGAP3* (c.1759G \> C; p.G587R; rs762072609), *SLC1A2* (c.1091G \> A; p.R364H; rs147645566), and *CLTCL1* (c.1061G \> A; p.R354H; rs201506683) (Table [2](#mgg3996-tbl-0002){ref-type="table"}). Additionally, two pathogenic mutations were observed, *MYBPC3* (p.E334K) and *DUOX2* (p.K530X).

###### 

Summary of the phenotypic features of patients with autism spectrum disorder and the relevant findings of the study

  Patient   Rare variants in autism‐related genes involved pathways[a](#mgg3996-note-0003){ref-type="fn"}   ABCT (47 items)                                  
  --------- ----------------------------------------------------------------------------------------------- ----------------- ---- ---- --- --- ---- --- --- ----
  ASD23                                                                                                                       \+        3   6   9    4   6   28
  ASD24                                                                                                                                 1   6   7    6   7   27
  ASD25     \+                                                                                              \+                \+   \+   3   4   3    5   5   20
  ASD26     \+                                                                                              \+                \+        4   4   8    5   6   27
  ASD27                                                                                                                                 4   8   12   6   6   36

Rare variants in autism‐related genes (as shown in Table [2](#mgg3996-tbl-0002){ref-type="table"}) are involved in several pathways.
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Patient 3, a 15‐year‐old male, had an ABC‐T score of 20 (Table [3](#mgg3996-tbl-0003){ref-type="table"}). The 750K microarray showed a 1q21.1q21.2 duplication (1949.031 kbp) containing 10 OMIM genes (*HYDIN2*, *PRKAB2*, *FMO5*, *CHD1L*, *BCL9*, *ACP6*, *GJA5*, *GJA8*, *GPR89B*, and *NBPF11*). WES revealed seven rare variants in *WFS1* (c.2144G \> T; p.S715I; rs772022154), *TNN* (c.1681T \> C; p.Y561H; rs777370361), *JMJD1C* (c.6344T \> G; p.F2115C; novel) (Figure [1](#mgg3996-fig-0001){ref-type="fig"}a), *APP* (c.1748A \> G; p.E583G; rs778495527), *SYNE1* (c.9878C \> T; p.S3293F; rs770774159), *MPP6* (c.61G \> A; p.D21N; rs771283348), and *MCC* (c.60_61insAGC; p.G21delinsSG; rs72442525) (Table [2](#mgg3996-tbl-0002){ref-type="table"}). WFS1, TNN, APP, and MCC are involved in the negative regulation of Wnt and canonical Wnt signaling pathways (GO:0030178 and GO:0090090), negative regulation of signaling transduction (GO:0009968) and endoplasmic reticulum calcium ion homeostasis (GO:0032469). Moreover, a pathogenic mutation in the *EYS* gene (p.C2139Y) was observed.

![Chromatograms of the heterozygous missense variants in *JMJD1C* (a), *TCF12* (b), *BIRC6* (c), and de novo variant in *NHS* (d)](MGG3-7-e996-g001){#mgg3996-fig-0001}

Patient 4, a 6‐year‐old male, had an ABC‐T score of 27 (Table [3](#mgg3996-tbl-0003){ref-type="table"}). The 750K microarray revealed no abnormalities. WES revealed seven rare variants in *TSC2* (c.5418T \> G; p.F1806L; rs200004126), *SETBP1* (c.2842C \> T; p.R948C; rs751366974), *TCF12* (c.770G \> A; p.R257H; novel) (Figure [1](#mgg3996-fig-0001){ref-type="fig"}b), *LZTS2* (c.1259G \> A; p.R420Q; rs759282265), *BIRC6* (c.6600G \> T; p.Q2200H; novel) (Figure [1](#mgg3996-fig-0001){ref-type="fig"}c), *EPHA6* (c.527A \> C; p.N176T), and *ASMT* (c.451G \> A; p.G151S; rs192710293) (Table [2](#mgg3996-tbl-0002){ref-type="table"}). TSC2, LZTS2 and BIRC6 are involved in the negative regulation of Wnt and canonical Wnt signaling pathways (GO:0030178 and GO:0090090) and negative regulation of signaling transduction (GO:0009968). No pathogenic mutations were detected.

Patient 5, a 10‐year‐old male, had an ABC‐T score of 36 (Table [3](#mgg3996-tbl-0003){ref-type="table"}). The 750K microarray showed a 9q33.1 duplication (1090.359 kbp) containing three OMIM genes (*PAPPA*, *ASTN2*, and *TRIM32*). WES revealed one de novo variant in the *NHS* (c.20T \> C; p.I7T) gene (Table [2](#mgg3996-tbl-0002){ref-type="table"} and Figure [1](#mgg3996-fig-0001){ref-type="fig"}d). *NHS* p.I7T has not been previously reported. Additionally, a pathogenic mutation in the *FLG* gene (p.E2422X) was observed.

The mutations in our five patients were further confirmed by Sanger sequencing of DNA from both parents to determine the origins of mutation or to reveal de novo mutations.

4. DISCUSSION {#mgg3996-sec-0013}
=============

In this study, WES was performed to identify possible ASD causal variants in five Taiwanese families; one novel de novo variant in one trio and rare variants in each trio were successfully identified. These genes are involved mainly in the negative regulation of Wnt and canonical Wnt signaling pathways, negative regulation of signaling transduction and endoplasmic reticulum calcium ion homeostasis. We detected no association of the ABC‐T score with a particular pathway. However, possible causal variants may be missed if located within a noncoding region; thus, WGS will be necessary in future studies.

Three ASD patients (ASD25, ASD26, and ASD27) were found to carry a novel missense variant of four genes (*JMJD1C*, *TCF12*, *BIRC6*, and *NHS*) (Table [2](#mgg3996-tbl-0002){ref-type="table"}). *JMJD1C* encodes a putative histone demethylase and is involved in the epigenetic control of gene transcription. This study identified a variant of *JMJD1C*, c.6344T \> G, which results in the substitution of phenylalanine by cysteine (p.F2115C). The p.F2115C mutation is in the JmjC domain, a domain family that is part of the cupin metalloenzyme superfamily. Mutations in this gene are associated with Rett syndrome and intellectual disability (Saez et al., [2016](#mgg3996-bib-0032){ref-type="ref"}). *TCF12* encodes a member of the basic helix‐loop‐helix E‐protein family that recognizes the consensus‐binding site (E‐box) CANNTG. This study identified a variant, c.770G \> A, which results in substitution of an arginine by histidine (p.R257H) in *TCF12*. *BIRC6* encodes an inhibitor of apoptosis protein with baculoviral inhibition of apoptosis protein repeat (BIR) and ubiquitin‐conjugating enzyme E2, catalytic (UBCc) domains. This study found a variant of *BIRC6*, c.6600G \> T, which results in substitution of a glutamine by histidine (p.Q2200H). *NHS* encodes a protein with four conserved nuclear localization signals that function in brain development. This study identified a variant, c.20T \> C, which results in substitution of isoleucine by threonine (p.I7T) in *NHS*. Mutations in this gene are associated with Nance--Horan syndrome (Shoshany et al., [2017](#mgg3996-bib-0036){ref-type="ref"}). These variants were not found among the 277,264 alleles in the GnomAD database and were predicted to be damaging in silico by SIFT and to be likely damaging by Polyphen2.

Most of the variants identified in this study were found in autosomal genes, whereas one was identified in the X‐Y pseudoautosomal gene, *ASMT*, which has been reported to be associated with the autism phenotype and sleep disturbance (Cai et al., [2008](#mgg3996-bib-0007){ref-type="ref"}; Wang et al., [2013](#mgg3996-bib-0039){ref-type="ref"}). In the present study, we identified one reported missense variant, pG151S, in the Taiwanese population with ASD. Additionally, we detected no obvious dominant or recessive compound heterozygous mutations in ASD‐related genes.

By considering pathogenic mutations with ClinVar, we found variants in four of five probands (80%). The pathogenic mutations were detected in *SMPD1*, *FUT2*, *BCHE*, *MYBPC3*, *DUOX2*, *EYS*, and *FLG2* in four different patients (Table [4](#mgg3996-tbl-0004){ref-type="table"}). *SMPD1* encodes a lysosomal acid sphingomyelinase that converts sphingomyelin to ceramide. Defects in this gene are a cause of Parkinson\'s disease (Mao et al., [2017](#mgg3996-bib-0024){ref-type="ref"}). *FUT2* encodes a Golgi stack membrane protein and is highly associated with the development of inflammatory bowel disease (Wu et al., [2017](#mgg3996-bib-0040){ref-type="ref"}). *BCHE* encodes a cholinesterase enzyme and is a member of the type‐B carboxylesterase/lipase family of proteins. Some of the genetic variants are prone to the development of prolonged apnea following administration of the muscle relaxant succinylcholine (Panhuizen, Snoeck, Levano, & Girard, [2010](#mgg3996-bib-0030){ref-type="ref"}). *BCHE* p.T343fs has been reported in colon adenocarcinomas and esophageal carcinomas. *MYBPC3* encodes the cardiac isoform of myosin‐binding protein C. Mutations in *MYBPC3* are one cause of familial hypertrophic cardiomyopathy (Aurensanz Clemente et al., [2017](#mgg3996-bib-0002){ref-type="ref"}). *MYBPC3* is one of the American College of Medical Genetics and Genomics genes. *DUOX2* encodes a glycoprotein and a member of the NADPH oxidase family. *DUOX2* mutations are the most powerful genetic predisposing factors for thyroid dyshormonogenesis (Chen et al., [2018](#mgg3996-bib-0009){ref-type="ref"}). *EYS* is mutated in autosomal recessive retinitis pigmentosa (Mucciolo et al., [2018](#mgg3996-bib-0027){ref-type="ref"}). *FLG2* encodes an intermediate filament‐associated protein that functions in aggregation and the collapse of keratin intermediate filaments in mammalian epidermis. Mutations in this gene are associated with ichthyosis vulgaris and atopic dermatitis (Hassani et al., [2018](#mgg3996-bib-0013){ref-type="ref"}).

###### 

Summary of the pathogenic mutations detected in this study[a](#mgg3996-note-0004){ref-type="fn"}

+------------+--------------+--------------+-------------------+-----------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------+-----------------------------------------------+
| Proband ID | Gene         | Base Change  | Amino Acid Change | OMIM                  | Gene function                                                                                                                                                            | Biological process (s)                                                                                                                | Human disease                                                                     | Reported link to other neurological disorders |
+============+==============+==============+===================+=======================+==========================================================================================================================================================================+=======================================================================================================================================+===================================================================================+===============================================+
| ASD−23     | *SMPD1*      | c.557C \> T  | p.P186L           | 607608                | Sphingomyelin phosphodiesterase 1                                                                                                                                        | Nervous system development                                                                                                            | Niemann‐Pick disease, type A and B                                                | Parkinson\'s disease                          |
+------------+--------------+--------------+-------------------+-----------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------+-----------------------------------------------+
| *FUT2*     | c.604C \> T  | p.R202X      | 182100            | Fucosyltransferase 2  | Protein glycosylation                                                                                                                                                    | Vitamin B12 plasma level                                                                                                              | Deficiency in vitamin B12, clinically associated with neurodegenerative disorders |                                               |
|            |              |              |                   |                       |                                                                                                                                                                          |                                                                                                                                       |                                                                                   |                                               |
|            |              |              |                   |                       |                                                                                                                                                                          | Crohn disease                                                                                                                         |                                                                                   |                                               |
+------------+--------------+--------------+-------------------+-----------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------+-----------------------------------------------+
| *BCHE*     | c.1027dupA   | p.T343fs     | 177400            | Butyrylcholinesterase | Choline metabolic process, Neuroblast differentiation                                                                                                                    | Butyrylcholinesterase deficiency                                                                                                      | No                                                                                |                                               |
|            |              |              |                   |                       |                                                                                                                                                                          |                                                                                                                                       |                                                                                   |                                               |
|            |              |              |                   |                       |                                                                                                                                                                          | Apnea, postanesthetic, susceptibility to, due to BCHE deficiency                                                                      |                                                                                   |                                               |
+------------+--------------+--------------+-------------------+-----------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------+-----------------------------------------------+
| ASD−24     | *MYBPC3*     | c.1000G \> A | p.E334K           | 600958                | Myosin binding protein C, cardiac                                                                                                                                        | Cardiac muscle contraction, Ventricular cardiac muscle tissue morphogenesis                                                           | Cardiomyopathy, hypertrophic                                                      | No                                            |
+------------+--------------+--------------+-------------------+-----------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------+-----------------------------------------------+
| *DUOX2*    | c.1588A \> T | p.K530X      | 606759            | Dual oxidase 2        | Thyroid gland development, Thyroid hormone generation                                                                                                                    | Thyroid dyshormonogenesis                                                                                                             | No                                                                                |                                               |
+------------+--------------+--------------+-------------------+-----------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------+-----------------------------------------------+
| ASD−25     | *EYS*        | c.6416G \> A | p.C2139Y          | 612424                | Required to maintain the integrity of photoreceptor cells.                                                                                                               | Detection of light stimulus involved in visual perception, Skeletal muscle tissue regeneration                                        | Retinitis pigmentosa                                                              | No                                            |
+------------+--------------+--------------+-------------------+-----------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------+-----------------------------------------------+
| ASD−26     |              |              |                   |                       |                                                                                                                                                                          |                                                                                                                                       |                                                                                   |                                               |
+------------+--------------+--------------+-------------------+-----------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------+-----------------------------------------------+
| ASD−27     | *FLG*        | c.7264G \> T | c.E2422X          | 135940                | Aggregates keratin intermediate filaments and promotes disulfide‐bond formation among the intermediate filaments during terminal differentiation of mammalian epidermis. | Cornification, Establishment of skin barrier, Keratinocyte differentiation, Multicellular organism development, Peptide cross‐linking | Ichthyosis vulgaris                                                               | No                                            |
+------------+--------------+--------------+-------------------+-----------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------+-----------------------------------------------+

Pathogenic mutations, according to the ClinVar database.
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In conclusion, we report on five ASD patients with rare variants and one patient with a de novo variant. However, this association study was performed with only a small number of cases; therefore, further studies with larger sample sizes are needed.
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